Global News

Eisai establishes AiM Institute for precision medicines

Tuesday, September 20, 2016

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., has announced the launch of the Eisai Andover innovative Medicines (AiM) Institute, a discovery innovation unit within the greater Boston biopharma hub. With 90 integrated scientists at a state-of-the-art research facility in Andover, Massachusetts, the Institute is focused on executing novel therapeutic targets validated by human genetics and related data to discover and develop precision medicines for some of the hardest-to-treat medical conditions including dementia, cancer and auto-immune diseases.

[Read More]

EMD Serono appoints Craig Millian SVP, Neurology And Immunology

Tuesday, September 20, 2016

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, has announced the appointment of Craig Millian as senior vice president, Neurology and Immunology. Millian most recently served as senior vice president, head of U.S. Fertility and Endocrinology at EMD Serono. In his new role, he will lead the strategic direction of the company’s U.S. Neurology and Immunology franchise.

[Read More]

Tactics for recruiting diverse patient populations

Monday, September 19, 2016

The Pulse on Patient Recruitment by Ashley Tointon

Patient Recruitment strategies are not the same for all patient populations. The recruitment strategies that work well in a phase III psoriasis study will not be the same as those that work well for a phase II pediatric type 2 diabetes trial. Recruitment strategies will differ among different genders, ethnicities, incomes and ages. In order to develop a sound strategy, you first must understand your audience and then dive deeper to understand preferred mediums and uncover credibility factors that should be considered in the messaging and the medium of recruitment activities.

[Read More]

Catalent to acquire Pharmatek

Thursday, September 15, 2016

Catalent, a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has announced an agreement for Catalent, through its wholly owned subsidiary, Catalent Pharma Solutions, to acquire Pharmatek Laboratories, a West Coast, U.S.-based specialist in drug development and clinical manufacturing.

[Read More]

Allergan to acquire Vitae Pharmaceuticals for $639M

Thursday, September 15, 2016

Allergan, a global pharmaceutical company, and Vitae Pharmaceuticals, a clinical-stage biotechnology company, have entered into a definitive agreement under which Allergan will acquire Vitae for $21.00 per share, in cash, for a total transaction value of approximately $639 million. The Boards of Directors of both companies have unanimously approved the transaction.

[Read More]

Exco InTouch appoints Steve Powell as chief operating officer

Wednesday, September 14, 2016

Exco InTouch, a provider of digital patient engagement and data capture solutions for clinical research and healthcare providers, has appointed Steve Powell as the company’s chief operating officer and president. In this newly created position, Powell will be responsible for all aspects of Exco InTouch’s operational delivery including services and technology.  

[Read More]